- Home
- AMSF vs ORKA Comparison
AMSF vs ORKA Comparison
Compare AMSF & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- ORKA
- Stock Information
- Founded
- AMSF 1985
- ORKA 2004
- Country
- AMSF United States
- ORKA United States
- Employees
- AMSF N/A
- ORKA N/A
- Industry
- AMSF Accident &Health Insurance
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AMSF Finance
- ORKA Health Care
- Exchange
- AMSF Nasdaq
- ORKA Nasdaq
- Market Cap
- AMSF 869.6M
- ORKA 354.2M
- IPO Year
- AMSF 2005
- ORKA N/A
- Fundamental
- Price
- AMSF $43.53
- ORKA $13.29
- Analyst Decision
- AMSF Buy
- ORKA Strong Buy
- Analyst Count
- AMSF 2
- ORKA 8
- Target Price
- AMSF $59.50
- ORKA $39.71
- AVG Volume (30 Days)
- AMSF 151.7K
- ORKA 337.9K
- Earning Date
- AMSF 07-24-2025
- ORKA 08-15-2025
- Dividend Yield
- AMSF 10.52%
- ORKA N/A
- EPS Growth
- AMSF N/A
- ORKA N/A
- EPS
- AMSF 2.48
- ORKA N/A
- Revenue
- AMSF $301,216,000.00
- ORKA N/A
- Revenue This Year
- AMSF $1.69
- ORKA N/A
- Revenue Next Year
- AMSF $6.54
- ORKA N/A
- P/E Ratio
- AMSF $17.49
- ORKA N/A
- Revenue Growth
- AMSF N/A
- ORKA N/A
- 52 Week Low
- AMSF $42.48
- ORKA $5.49
- 52 Week High
- AMSF $60.24
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- AMSF 39.91
- ORKA N/A
- Support Level
- AMSF $42.48
- ORKA N/A
- Resistance Level
- AMSF $44.27
- ORKA N/A
- Average True Range (ATR)
- AMSF 0.89
- ORKA 0.00
- MACD
- AMSF 0.07
- ORKA 0.00
- Stochastic Oscillator
- AMSF 42.68
- ORKA 0.00
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.